About Paul Kelly
Paul Kelly is a president and director at EnZeta Immunotherapies.
Paul Kelly first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Paul Kelly in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Paul Kelly works with at each company, as listed on that company's latest Form D.
EnZeta Immunotherapies, Inc. · Form D/A, Mar 6, 2026
ST
Sergio Traversa
Director